Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Associate Professor Miriam T. Rademaker

Miriam Rademaker Research Associate Professor

BSc(Cant) PhD(Otago)

Email miriam.rademaker@otago.ac.nz

Department of Medicine
University of Otago, Christchurch
PO Box 4345
Christchurch
New Zealand

Current roles

  • Research Associate Professor, Department of Medicine
  • Co-Director, Physiology Division, Christchurch Heart Institute
  • Principle Investigator of physiological based studies
  • Member of Faculty of the Christchurch School of Medicine
  • Member of The Canterbury Medical Research Society
  • Editorial Board, American Journal of Physiology: Reg., Int.
  • Editorial Board, Clinical Science

Research interests

Research focus is on the integrated cardiovascular, endocrine and renal control of pressure/volume homeostasis.

Particular emphasis is placed on the role that key vasoactive hormones (such as the natriuretic peptides, adrenomedullins, endothelin and the renin-angiotensin-aldosterone system) play in the pathophysiology of circulatory diseases such as hypertension, myocardial infarction and heart failure, and ways of manipulating these systems in order to prevent and treat these diseases.

Over the past decade interest has widened to include the novel urocortin family of peptides, phosphodiesterase 9 inhibition and natriuretic peptide analogues engineered to have distinct vasodilatory or renal activity, as well as renal dysfunction in heart failure (one of the most important risk factors for morbidity and mortality in this disease) and novel implantable devices that may potentially be used to identify early decompensation in heart failure and to optimise anti-failure treatment.

^ Top of page

Publications

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2019). Adrenomedullin 2 increases cardiac sympathetic nerve activity in parallel to heart rate in normal conscious sheep. Physiological Reports, 7(10), e14096. doi: 10.14814/phy2.14096

Mbikou, P., Rademaker, M. T., Charles, C. J., Richards, M. A., & Pemberton, C. J. (2019). Cardiovascular effects of DWORF (dwarf open reading frame) peptide in normal and ischaemia/reperfused isolated rat hearts. Peptides. Advance online publication. doi: 10.1016/j.peptides.2019.170192

Scott, N. J. A., Rademaker, M. T., Charles, C. J., Espiner, E. A., & Richards, A. M. (2019). Hemodynamic, hormonal, and renal actions of phosphodiesterase-9 inhibition in experimental heart failure. JACC, 74(7), 889-901. doi: 10.1016/j.jacc.2019.05.067

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2018). Systemic Angiotensin II does not increase cardiac sympathetic nerve activity in normal conscious sheep. Bioscience Reports, 38(5), BSR20180513. doi: 10.1042/bsr20180513

Adão, R., Mendes-Ferreira, P., Santos-Ribeiro, D., Maia-Rocha, C., Pimentel, L. D., Pinto, C., … Rademaker, M. T., … Brás-Silva, C. (2018). Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 114(8), 1165-1177. doi: 10.1093/cvr/cvy076

Chapter in Book - Research

Richards, M., & Rademaker, M. (2013). Urocortins. In A. Kastin (Ed.), Handbook of biologically active peptides. (2nd ed.) (pp. 1428-1436). San Diego, CA: Academic Press. doi: 10.1016/B978-0-12-385095-9.00194-9

Rademaker, M. T., & Espiner, E. A. (2002). Cardiovascular hormones. In G. M. Besser & M. O. Thorner (Eds.), Comprehensive Clinical Endocrinology. (3rd ed.) (pp. 485-499). Edinburgh: Mosby.

Rademaker, M. T., & Espiner, E. A. (2001). The endrocrine heart. In K. Becker (Ed.), Principles and Practice of Endocrinology and Metabolism (3rd edition). (pp. 1622-1634). Philadelphia: Lippincott Williams and Wilkins.

Rademaker, M. T., & Espiner, E. A. (2001). Hormones of the cardiovascular system. In L. J. DeGroot & J. L. Jameson (Eds.), Endocrinology. (4th ed.) (pp. 1791-1809). Philadelphia: W. B. Saunders Company.

Richards, A. M., Lainchbury, J. G., Nicholls, M. G., & Rademaker, M. T. (2000). Adrenomedullin in heart failure: Biochemical curiosity or pathophysiological player? In J. J. V. McMurray & J. G. F. Cleland (Eds.), Heart Failure in Clinical Practice. (2nd ed.) (pp. 105-125). London: Martin Dunitz.

^ Top of page

Chapter in Book - Other

Richards, M., Troughton, R., Espiner, E., Cameron, V., Ellmers, L., Pilbrow, A., Charles, C., Rademaker, M., Pemberton, C., & Yandle, T. (2013). Christchurch Heart Institute. In P. Joyce, G. Nicholls, K. Thomas & T. Wilkinson (Eds.), The Christchurch experience: 40 years of research and teaching. (pp. 68-74). Christchurch, New Zealand: University of Otago.

Rademaker, M. T., & Espiner, E. (2010). Hormones of the cardiovascular system. In J. L. Jameson & L. J. De Groot (Eds.), Endocrinology: Adult and pediatric (Vol. II). (6th ed.) (pp. 2036-2052). Philadelphia, PA: Saunders.

Rademaker, M. T., & Espiner, E. A. (2006). Hormones of the cardiovascular system. In L. J. DeGroot & J. L. Jameson (Eds.), Endocrinology (Vol. 3). (5th ed.) (pp. 2549-2566). Philadelphia: Elsevier Saunders.

^ Top of page

Journal - Research Article

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2019). Adrenomedullin 2 increases cardiac sympathetic nerve activity in parallel to heart rate in normal conscious sheep. Physiological Reports, 7(10), e14096. doi: 10.14814/phy2.14096

Scott, N. J. A., Rademaker, M. T., Charles, C. J., Espiner, E. A., & Richards, A. M. (2019). Hemodynamic, hormonal, and renal actions of phosphodiesterase-9 inhibition in experimental heart failure. JACC, 74(7), 889-901. doi: 10.1016/j.jacc.2019.05.067

Mbikou, P., Rademaker, M. T., Charles, C. J., Richards, M. A., & Pemberton, C. J. (2019). Cardiovascular effects of DWORF (dwarf open reading frame) peptide in normal and ischaemia/reperfused isolated rat hearts. Peptides. Advance online publication. doi: 10.1016/j.peptides.2019.170192

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2018). Systemic Angiotensin II does not increase cardiac sympathetic nerve activity in normal conscious sheep. Bioscience Reports, 38(5), BSR20180513. doi: 10.1042/bsr20180513

Adão, R., Mendes-Ferreira, P., Santos-Ribeiro, D., Maia-Rocha, C., Pimentel, L. D., Pinto, C., … Rademaker, M. T., … Brás-Silva, C. (2018). Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 114(8), 1165-1177. doi: 10.1093/cvr/cvy076

Wong, L. L., Rademaker, M. T., Saw, E. L., Lew, K. S., Ellmers, L. J., Charles, C. J., Richards, A. M., & Wang, P. (2017). Identification of novel microRNAs in the sheep heart and their regulation in heart failure. Scientific Reports, 7(1), 8250. doi: 10.1038/s41598-017-08574-x

Ellmers, L. J., Rademaker, M. T., Charles, C. J., Yandle, T. G., & Richards, A. M. (2016). (PRO)renin receptor blockade ameliorates cardiac injury and remodeling and improves function after myocardial infarction. Journal of Cardiac Failure, 22(1), 64-72. doi: 10.1016/j.cardfail.2015.08.341

Rademaker, M. T., Ellmers, L. J., Charles, C. J., & Richards, A. M. (2015). Urocortin 2 protects heart and kidney structure and function in an ovine model of acute decompensated heart failure: Comparison with dobutamine. International Journal of Cardiology, 197, 56-65. doi: 10.1016/j.ijcard.2015.06.011

Adão, R., Santos-Ribeiro, D., Rademaker, M. T., Leite-Moreira, A. F., & Brás-Silva, C. (2015). Urocortin 2 in cardiovascular health and disease. Drug Discovery Today, 20(7), 906-914. doi: 10.1016/j.drudis.2015.02.012

Charles, C. J., Rademaker, M. T., Melton, I. C., Gutfinger, D., Eigler, N. L., Qu, F., & Troughton, R. W. (2015). Thoracic impedance measures tissue characteristics in the vicinity of the electrodes, not intervening lung water: Implications for heart failure monitoring. Journal of Clinical Monitoring & Computing, 29(1), 65-76. doi: 10.1007/s10877-014-9570-x

Ellmers, L. J., Scott, N. J. A., Cameron, V. A., Richards, A. M., & Rademaker, M. T. (2015). Chronic urocortin 2 administration improves after cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction. Journal of Cardiovascular Pharmacology, 65(3), 269-275. doi: 10.1097/FJC.0000000000000190

Rademaker, M. T., Charles, C. J., & Richards, M. (2014). Sheep for the study of the urocortins and other hormones. Cardiovascular Endocrinology, 3(1), 39-43. doi: 10.1097/XCE.0000000000000024

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2014). Low-dose B-type natriuretic peptide raises cardiac sympathetic nerve activity in sheep. American Journal of Physiology: Regulatory, Integrative & Comparative Physiology, 307(2), R206-R211. doi: 10.1152/ajpregu.00404.2013

Roberts, A., Trainor, K. E., Weeks, B., Jackson, N., Troughton, R. W., Charles, C. J., Rademaker, M. T., Melton, I. C., Crozier, I. G., … Clubb, Jr, F. J. (2013). Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor. Journal of Histotechnology, 36(1), 17-27. doi: 10.1179/2046023613Y.0000000021

Trainor, K. E., Roberts, A., Weeks, B., Jackson, N., Troughton, R. W., Charles, C. J., Rademaker, M. T., Melton, I. C., Crozier, I. G., … Clubb, Jr, F. J. (2013). Comparative pathology of an implantable left atrial pressure sensor. ASAIO Journal, 59(5), 486-492. doi: 10.1097/MAT.0b013e31829bdffd

Rademaker, M. T., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2013). Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure. Circulation: Heart Failure, 6(4), 825-832. doi: 10.1161/circheartfailure.112.000205

Rademaker, M. T., Yandle, T. G., Ellmers, L. J., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2012). Hemodynamic, hormonal, and renal effects of (pro)renin receptor blockade in experimental heart failure. Circulation: Heart Failure, 5, 645-652. doi: 10.1161/circheartfailure.112.967059

Rademaker, M. T., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2012). Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure. Clinical Science, 122(9), 429-437. doi: 10.1042/cs20110483

Patel, K., Rademaker, M. T., Kirkpatrick, C. M. J., Charles, C. J., Fisher, S., Yandle, T. G., & Richards, A. M. (2012). Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep. British Journal of Pharmacology, 166(6), 1916-1925. doi: 10.1111/j.1476-5381.2012.01904.x

Rademaker, M. T., Charles, C. J., Ellmers, L. J., Lewis, L. K., Nicholls, M. G., & Richards, A. M. (2011). Prolonged urocortin 2 administration in experimental heart failure: Sustained hemodynamic, endocrine, and renal effects. Hypertension, 57, 1136-1144. doi: 10.1161/HYPERTENSIONAHA.111.173203

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, M. (2011). Urocortin 3 inhibits cardiac sympathetic nerve activity in conscious sheep. Journal of Cardiovascular Pharmacology, 58(4), 418-423. doi: 10.1097/FJC.0b013e31822707a4

Rademaker, M. T., Charles, C. J., Nicholls, G., & Richards, M. (2011). Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure. Journal of Hypertension, 29, 1787-1795. doi: 10.1097/HJH.0b013e3283493776

Rademaker, M. T., Charles, C. J., Melton, I. C., Richards, A. M., Frampton, C. M., Siou, J., … Troughton, R. W. (2011). Monitoring of heart failure: Comparison of left atrial pressure with intrathoracic impedance and natriuretic peptide measurements in an experimental model of ovine heart failure. Clinical Science, 120(5), 207-217. doi: 10.1042/CS20100388

Charles, C. J., Rademaker, M. T., & Richards, A. M. (2011). Hemodynamic, hormonal, and renal actions of adrenomedullin-5 in normal conscious sheep. Journal of Cardiovascular Pharmacology, 58(1), 25-31. doi: 10.1097/FJC.0b013e31821a9473

Charles, C. J., Rademaker, M. T., Nicholls, M. G., & Richards, A. M. (2010). Adrenomedullin 2 attenuates the pressor but not adrenal responses to angiotensin II in conscious sheep. Peptides, 31, 878-882. doi: 10.1016/j.peptides.2010.02.010

Charles, C. J., Jardine, D. L., Rademaker, M. T., & Richards, A. M. (2010). Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. Journal of Endocrinology, 204, 181-189. doi: 10.1677/JOE-08-0505

Rademaker, M. T., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2009). Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circulation: Heart Failure, 2(6), 532-540. doi: 10.1161/CIRCHEARTFAILURE.109.861336

Rademaker, M. T., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2008). Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clinical Science, 114(10), 635-642. doi: 10.1042/CS20070364

Charles, C. J., Jardine, D. L., Nicholls, M. G., Rademaker, M. T., & Richards, A. M. (2008). Urocortin 1 exhibits potent inhibition of cardiac sympathetic nerve activity in conscious sheep. Journal of Hypertension, 26(1), 53-60.

Rademaker, M. T., Charles, C. J., Nicholls, M. G., & Richards, A. M. (2008). Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure. Circulation: Heart Failure, 1, 134-142. doi: 10.1161/circheartfailure.107.755504

Davis, M. E., Pemberton, C. J., Yandle, T. G., Fisher, S. F., Lainchbury, J. G., Frampton, C. M., Rademaker, M. T., & Richards, M. (2007). Urocortin 2 infusion in human heart failure. European Heart Journal, 28(21), 2589-2597.

Davis, M. E., Pemberton, C. J., Yandle, T. G., Fisher, S. F., Lainchbury, J. G., Frampton, C. M., Rademaker, M. T., & Richards, A. M. (2007). Urocortin 2 infusion in healthy humans: Hemodynamic, neurohormonal, and renal responses. JACC, 49(4), 461-471.

Charles, C. J., Rademaker, M. T., & Richards, A. M. (2007). Urocortin 1 modulates the neurohumoral response to acute nitroprusside-induced hypotension in sheep. Clinical Science, 112, 485-491.

Rademaker, M. T., Charles, C. J., & Richards, A. M. (2007). Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. American Journal of Physiology: Heart & Circulatory Physiology, 293, H1536-H1544. doi: 10.1152/ajpheart.00377.2007

Jarvis, M. D., Rademaker, M. T., Ellmers, L. J., Currie, M. J., McKenzie, J. L., Palmer, B. R., Frampton, C. M., Richards, A. M., & Cameron, V. A. (2006). Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: Response to cytokines and natriuretic peptide receptor expression profiles. American Journal of Physiology: Heart & Circulatory Physiology, 291, H1952-H1958. doi: 10.1152/ajpheart.00764.2005

Charles, C. J., Prickett, T. C. R., Espiner, E. A., Rademaker, M. T., Richards, A. M., & Yandle, T. G. (2006). Regional sampling and the effects of experimental heart failure in sheep: Differential responses in A, B and C-type natriuretic peptides. Peptides, 27(1), 62-68. doi: 10.1016/j.peptides.2005.06.019

Rademaker, M. T., Cameron, V. A., Charles, C. J., & Richards, A. M. (2006). Urocortin 3: Haemodynamic, hormonal, and renal effects in expermental heart failure. European Heart Journal, 27(17), 2088-2098.

Charles, C. J., Rademaker, M. T., & Richards, A. M. (2006). Hemodynamic, hormonal, and renal actions of adrenomedullin-2 in normal conscious sheep. Endocrinology, 147(4), 1871-1877.

Charles, C. J., Rademaker, M. T., Richards, A. M., & Yandle, T. G. (2006). Plasma urocortin 1 in sheep: Regional sampling and effects of experimental heart failure. Peptides, 27, 1801-1805.

Charles, C. J., Rademaker, M. T., & Richards, A. M. (2006). Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. Journal of Endocrinology, 189(3), 701-710.

Rademaker, M. T., & Richards, A. M. (2005). Cardiac natriuretic peptides for cardiac health. Clinical Science, 108, 23-36. doi: 10.1042/CS20040253

Davis, M. E., Pemberton, C. J., Yandle, T. G., Lainchbury, J. G., Rademaker, M. T., Nicholls, M. G., Frampton, C. M., & Richards, A. M. (2005). Effect of urocortin I infusion in humans with stable congestive cardiac failure. Clinical Science, 109(4), 381-388. doi: 10.1042/CS20050079

More publications...